Cocrystal Pharma, Inc.
COCP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $12,537 | $15,169 | $12,392 | $8,794 |
| Gross Profit | -$12,537 | -$15,169 | -$12,392 | -$8,794 |
| % Margin | – | – | – | – |
| R&D Expenses | $12,537 | $15,169 | $12,392 | $8,794 |
| G&A Expenses | $5,341 | $5,990 | $5,745 | $5,427 |
| SG&A Expenses | $5,341 | $5,990 | $5,745 | $5,427 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$12,537 | -$17,769 | $8,300 | -$8,794 |
| Operating Expenses | $5,341 | $3,390 | $26,437 | $5,427 |
| Operating Income | -$17,878 | -$18,559 | -$38,829 | -$14,221 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $374 | $575 | -$8 | $36 |
| Pre-Tax Income | -$17,504 | -$17,984 | -$38,837 | -$14,185 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17,504 | -$17,984 | -$38,837 | -$14,185 |
| % Margin | – | – | – | – |
| EPS | -1.72 | -0.002 | -4.77 | -1.85 |
| % Growth | -90,426.3% | 100% | -157.8% | – |
| EPS Diluted | -1.72 | -0.002 | -4.77 | -1.85 |
| Weighted Avg Shares Out | 10,174 | 9,651 | 8,143 | 7,689 |
| Weighted Avg Shares Out Dil | 10,174 | 9,651 | 8,143 | 7,689 |
| Supplemental Information | – | – | – | – |
| Interest Income | $537 | $640 | $0 | $0 |
| Interest Expense | $0 | $0 | $2 | $4 |
| Depreciation & Amortization | $126 | $189 | $185 | $190 |
| EBITDA | -$17,752 | -$20,970 | -$17,952 | -$14,031 |
| % Margin | – | – | – | – |